Artificial Hearts

Company addresses possible reimbursement for VentrAssist LVAS

Published in Medical Devices and Surgical Technology Week, November 7th, 2004

Ventracor, Ltd., (VCR), said there was evidence the cost of its artificial heart devices used in its pending U.S. clinical trials would be fully reimbursed and there was potential for reimbursement at some European centers for the current CE Mark trial.

Addressing the second annual Australian Biotechnology Expo at the Australian Stock Exchange in Sydney, Australia, Ventracor's Business Development and Clinical Director and the co-inventor of its VentrAssist left ventricular assist system (LVAS), Dr John Woodard, said:

"With our trial for European approval now well underway and recruitment proceeding very well, we are looking to begin our U.S....

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Devices and Surgical Technology Week

Source: Medical Devices and Surgical Technology Week (2004-11-07)

More Articles from Medical Devices and Surgical Technology Week

DNA Research
Novel techniques improve control of macromolecular reactions
Drug Delivery
Thrombin peptide-loaded microspheres improve bone healing in rabbits
Genetic Disorders
Novel assay improves diagnosis of myotonic dystrophy type 2
Genomics and Genetics
Java-based application facilitates microarray experiment tracking
Spinal Cord Injury
Pneumatic impact device enables accurate rat model of SCI
Abdominal Aortic Aneurysm
FDA approves medical device to treat AAA
More from this issue of Medical Devices and Surgical Technology Week

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry